Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
Armata Pharmaceuticals Q3 EPS $(0.24) Beats $(0.56) Estimate, Sales $3.171M Beat $450.000K Estimate
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Why Is Armata Pharma Stock Gaining Monday?
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Armata Pharma Promotes David House To CFO
Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.